Efficacy of omalizumab in severe asthma with fungal sensitisation: a case report.
Severe asthma with fungal sensitisation (SAFS) is characterized by poor symptoms control and frequent hospital admissions for exacerbations despite treatment with high dose inhaled steroids, long-acting beta-2 agonists and leukotriene receptor antagonists. Treatment with oral steroids is usually necessary and courses of antifungal therapy may improve asthma symptoms. We report a case refractory to conventional inhaled therapies, continuous oral steroids and antifungal therapy courses, who was effectively treated with omalizumab.
Pneumology and Allergy Unit, Department of Internal Medicine, Ospedale Spirito Santo, Azienda USL Pescara, Pescara, Italy. f.distefano@aliceposta.it.
F
F
Di Stefano
Laboratory of Clinical Pathology and Microbiology, General Service Department, Azienda Ospedaliero-Universitaria "Ospedali Riuniti" di Ancona, Ancona, Italy.
B
B
Cinti
Allergy Unit, Department of Internal Medicine, Azienda Ospedaliero-Universitaria "Ospedali Riuniti" di Ancona, Ancona, Italy.
L
L
Antonicelli
D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D005658:Fungi / Q000276:immunology*; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D008875:Middle Aged; D000069444:Omalizumab
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000935:Antifungal Agents; D000069444:Omalizumab; D007073:Immunoglobulin E
Severe asthma with fungal sensitisation; omalizumab